Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants-Reference-Cited by-同舟云学术

Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants

Published:2021-08-13 Issue:6556 Volume:373 Page:818-823
ISSN:0036-8075
Container-title:Science
language:en
Short-container-title:Science

Author:

Yuan Meng¹^ORCID,Huang Deli²^ORCID,Lee Chang-Chun D.¹^ORCID,Wu Nicholas C.³⁴^ORCID,Jackson Abigail M.¹^ORCID,Zhu Xueyong¹^ORCID,Liu Hejun¹^ORCID,Peng Linghang²^ORCID,van Gils Marit J.⁵^ORCID,Sanders Rogier W.⁵⁶^ORCID,Burton Dennis R.²⁷^ORCID,Reincke S. Momsen⁸⁹^ORCID,Prüss Harald⁸⁹^ORCID,Kreye Jakob⁸⁹^ORCID,Nemazee David²^ORCID,Ward Andrew B.¹^ORCID,Wilson Ian A.¹¹⁰^ORCID

Affiliation:

1. Department of Integrative Structural and Computational Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

2. Department of Immunology and Microbiology, The Scripps Research Institute, La Jolla, CA 92037, USA.

3. Department of Biochemistry, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

4. Carl R. Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, Urbana, IL 61801, USA.

5. Department of Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers, Location AMC, University of Amsterdam, Amsterdam, Netherlands.

6. Department of Microbiology and Immunology, Weill Medical College of Cornell University, New York, NY 10021, USA.

7. Ragon Institute of MGH, Harvard, and MIT, Cambridge, MA 02139, USA.

8. German Center for Neurodegenerative Diseases (DZNE) Berlin, Berlin, Germany.

9. Department of Neurology and Experimental Neurology, Charité–Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität Berlin, and Berlin Institute of Health, Berlin, Germany.

10. Skaggs Institute for Chemical Biology, The Scripps Research Institute, La Jolla, CA 92037, USA.

Abstract

Defenses against SARS-CoV-2 variants Our key defense against the COVID-19 pandemic is neutralizing antibodies against the SARS-CoV-2 virus elicited by natural infection or vaccination. Recent emerging viral variants have raised concern because of their potential to escape antibody neutralization. Wang et al . identified four antibodies from early-outbreak convalescent donors that are potent against 23 variants, including variants of concern, and characterized their binding to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Yuan et al . examined the impact of emerging mutations in the receptor-binding domain of the spike protein on binding to the host receptor ACE2 and to a range of antibodies. These studies may be helpful for developing more broadly effective vaccines and therapeutic antibodies. —VV

Funder

U.S. Department of Energy

Bill and Melinda Gates Foundation

Argonne National Laboratory, Office of Science

Helmholtz Association

NIH

Netherlands Organisation for Scientific Research

German Research Foundation

Publisher

American Association for the Advancement of Science (AAAS)

Subject

Multidisciplinary

Reference104 articles.

1. M. Chand et al . Investigation of Novel SARS-CoV-2 Variant: Variant of Concern 202012/01. Technical Briefing 5 . Public Health England (2020); https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/959426/Variant_of_Concern_VOC_202012_01_Technical_Briefing_5.pdf.

2. Detection of a SARS-CoV-2 variant of concern in South Africa

3. N. R. Faria et al . “Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings” (2021); https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586.

4. V. Tchesnokova H. Kulakesara L. Larson V. Bowers E. Rechkina D. Kisiela Y. Sledneva D. Choudhury I. Maslova K. Deng K. Kutumbaka H. Geng C. Fowler D. Greene J. Ralston M. Samadpour E. Sokurenko Acquisition of the L452R mutation in the ACE2-binding interface of Spike protein triggers recent massive expansion of SARS-Cov-2 variants. bioRxiv 432189 [preprint]. 11 March 2021.432189

5. Neutralization of Variant Under Investigation B.1.617.1 With Sera of BBV152 Vaccinees

Cited by 291 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a potent recombinant scFv antibody against the SARS-CoV-2 by in-depth bioinformatics study: Paving the way for vaccine/diagnostics development;Computers in Biology and Medicine;2024-03

2. Navigating the Digital Transformation Terrain: Insights into the Interplay of Compensation, Incentives, and Managerial Behavior;Journal of the Knowledge Economy;2024-02-06

3. Predicting the immune escape of SARS-CoV-2 neutralizing antibodies upon mutation;Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease;2024-02

4. The Omicron XBB.1 Variant and Its Descendants: Genomic Mutations, Rapid Dissemination and Notable Characteristics;Biology;2024-02-01

5. Therapeutic antibodies and alternative formats against SARS-CoV-2;Antiviral Research;2024-02